Protagonist Therapeutics, Inc: cash and cash equivalents
Cash and cash equivalents for Protagonist Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Protagonist Therapeutics, Inc financial histories
What this measure means
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
Exact concept: us-gaap:CashAndCashEquivalentsAtCarryingValue. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2013-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 128,390,000 | USD | 2026-02-25 | 10-K · 0001104659-26-019696 |
| At date | 2024-12-31 | 97,249,000 | USD | 2026-02-25 | 10-K · 0001104659-26-019696 |
| At date | 2023-12-31 | 186,727,000 | USD | 2026-02-25 | 10-K · 0001104659-26-019696 |
| At date | 2022-12-31 | 125,744,000 | USD | 2025-02-21 | 10-K · 0001558370-25-001317 |
| At date | 2021-12-31 | 123,665,000 | USD | 2024-02-27 | 10-K · 0001558370-24-001850 |
| At date | 2020-12-31 | 117,358,000 | USD | 2023-03-15 | 10-K · 0001558370-23-003906 |
| At date | 2019-12-31 | 33,006,000 | USD | 2022-02-28 | 10-K · 0001558370-22-002385 |
| At date | 2018-12-31 | 82,233,000 | USD | 2021-03-10 | 10-K · 0001558370-21-002715 |
| At date | 2017-12-31 | 106,029,000 | USD | 2020-03-10 | 10-K · 0001558370-20-002334 |
| At date | 2016-12-31 | 21,084,000 | USD | 2019-03-12 | 10-K · 0001558370-19-001853 |
| At date | 2015-12-31 | 4,055,000 | USD | 2018-03-07 | 10-K · 0001558370-18-001637 |
| At date | 2014-12-31 | 9,324,000 | USD | 2017-03-07 | 10-K · 0001193125-17-073383 |
| At date | 2013-12-31 | 8,460,000 | USD | 2017-03-07 | 10-K · 0001193125-17-073383 |
Related financial histories
- Protagonist Therapeutics, Inc: total assets
- Protagonist Therapeutics, Inc: total liabilities
- Protagonist Therapeutics, Inc: stockholders equity
- Protagonist Therapeutics, Inc: net income or loss
- Protagonist Therapeutics, Inc: operating cash flow
- Protagonist Therapeutics, Inc: capital expenditure payments
- Protagonist Therapeutics, Inc: financing cash flow
- Protagonist Therapeutics, Inc: investing cash flow
- Protagonist Therapeutics, Inc: retained earnings or deficit
- Protagonist Therapeutics, Inc: basic weighted-average shares
- Protagonist Therapeutics, Inc: diluted weighted-average shares
- Protagonist Therapeutics, Inc: basic earnings per share
- Protagonist Therapeutics, Inc: diluted earnings per share
- Protagonist Therapeutics, Inc: income tax expense or benefit
- Protagonist Therapeutics, Inc: net property, plant and equipment
- Protagonist Therapeutics, Inc: share-based compensation expense
- Protagonist Therapeutics, Inc: operating income or loss
- Protagonist Therapeutics, Inc: current assets
- Protagonist Therapeutics, Inc: current liabilities
- Protagonist Therapeutics, Inc: current accounts payable
- Protagonist Therapeutics, Inc: operating expenses
- Protagonist Therapeutics, Inc: research and development expense
Inspect the source
- Entity
- Protagonist Therapeutics, Inc / CIK 0001377121
- Captured
- 2026-09-20T07:57:41.966Z
- SEC response SHA-256
2b94be6cb332c7a26793b651bf94eb30da9e478dc7b731b5866c637778540431
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001377121.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))